Generic Products (March 2019)

Pharmacy Times, March 2019 Respiratory, Volume 85, Issue 3

Generic products are featured.

ALBENDAZOLE TABLETS

MARKETED BY: Camber Pharmaceuticals

COMPARE TO: Albenza

Camber Pharmaceuticals recently announced the approval of Albendazole Tablets, its generic version of Albenza, to treat parasite and tapeworm infections. The tablets are available by prescription, with 2 doses of the 200-mg pills to treat the infection. Albendazole can treat 2 different conditions, hydatid and neurocysticercosis, both of which are caused by tapeworm larvae.

DOSAGE FORM: Tablets

FOR MORE INFORMATION: camberpharma.com

WIXELA INHUB

MARKETED BY: Mylan NV

COMPARE TO: Advair Diskus

The FDA recently approved Mylan’s Wixela Inhub (fluticasone propionate and salmeterol inhalation powder, USP). The drug is the first FDA approved generic of Advair Diskus, a treatment for asthma and chronic obstructive pulmonary disease (COPD). Wixela Inhub can be used twice daily by patients 4 years and older with asthma that is not being adequately controlled in the long term by patients with asthma who require both inhaled corticosteroids and long-acting beta antagonists for maintenance, for COPD maintenance, and for the reduction of COPD exacerbations.

DOSAGE FORM: Inhalation powder

FOR MORE INFORMATION: mylan.com

DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE EXTENDED-RELEASE TABLETS

MARKETED BY: Amerigen

COMPARE TO: Adderall XR Amerigen has received FDA approval for its mixed amphetamine salts dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release tablets. The drug is indicated for the treatment of attention deficit hyperactivity disorder in patients older than 6 years.

DOSAGE FORM: Extended-release capsule

FOR MORE INFORMATION: amerigenpharma.com

VIGABATRIN

MARKETED BY: Teva Pharmaceuticals

COMPARE TO: Sabril

Vigabatrin has been approved as a generic equivalent to Sabril as an adjunctive treatment for patients older than 10 years with refractory complex partial seizures who have not responded well to alternative treatments. The drug is not recommended as a first-line treatment, and the risks should be thoroughly assessed and compared with the benefits before starting treatment, as vigabatrin has serious risks, including vision loss.

DOSAGE FORM: Oral tablets

FOR MORE INFORMATION: tevapharm.com